Cabaletta Bio Q1 net loss widens as R&D costs rise

Cabaletta Bio

14/05/2026 12:14

Overview

US cell therapy developer's Q1 net loss widened from prior year

Research and development expenses rose, while general and administrative costs declined yr/yr

Company raised $150 mln in gross proceeds from May 2026 registered direct offering

Result Drivers

R&D SPENDING - Higher research and development expenses contributed to wider Q1 net loss

PIPELINE PROGRESS - Company advanced pivotal trials and expanded manufacturing capabilities for rese-cel

Company press release: ID:nGNX1gY0gH

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.39


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cabaletta Bio Inc is $13.50, about 276% above its May 13 closing price of $3.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)